| capecitabine / Generic mfg. |
ChiCTR-TRC-11001199: The efficacy of postoperative combination therapy with Thymosin alpha 1 and capecitabine for patients with hepatocellular carcinoma |
|
|
| Completed | 4 | 120 | | Thymosin Ta1 1.6mgS taken by ubcutaneous injection twice weekly for 6 months ;Capecitabine 0.5g , orally taken twice daily for 18months | West China Hospital, West China School of Medicine, Sichuan University; Ministry of National Science and Technology, National Science and Technology Major Project of China (2008ZX10002-025) | hepatocellular carcinoma | | | | |
ChiCTR-TNRC-08000052: Multicenter clinical control study of noncytotoxic drug- gastric carcinoma D2 radical correction- Capecitabine combined therapy in gastric carcinoma |
|
|
| Recruiting | 4 | 90 | | celecoxb 400mg/d, 2m; 200mg, qod, 5y Lanreotide 40mg, im, qm, 2m; 40mg, im, q6m, 5y ;Capecitabine 2500 mg/m2/d 2 w, resting1 w; 6 cycles ;Capecitabine 2500 mg/m2/d 2 w, resting 1 w; 6 cycles. celecoxb afterward 400mg/d,2m; 200mg, qod,5y Lanreotide 40mg, im, qm,2m; 40mg, im, q6m,5y | West China Hospital, Sichuan University; Level of the institution：, self-raised | Gastric carcinoma | | | | |
ChiCTR-TRC-10001108: Evaluation of short-term versus long-term preoperative radiotherapy with concurrent chemotherapy in the treatment of middle-lower rectal cancer: a multicenter randomized control trial |
|
|
| Completed | 4 | 400 | | long-term radiotherapy (GTV1 50.6Gy/CTV 41.8Gy/22) with concurrent chemotherapy (Capecitabine 850-1000mg/m2 bid, continuous for 14 days during radiotherapy) ;Short-term radiotherapy (30Gy/10）with concurrent chemotherapy (Capecitabine 850-1000mg/m2 bid, continuous for 14 days during radiotherapy) | Beijing Cancer Hospital; Beijing Cancer Hospital, Beijing Cancer Hospital | Rectal cancer | | | | |
ChiCTR-TRC-13003886: A Randomized, Controlled, Multicenter Clinical Trial of Kangai Injection in Combination with Chemotherapy XELOX in Treatment of Colorectal Cancer |
|
|
| Completed | 4 | 150 | | Kangai injection 60ml ivgtt D1-14 Q21d, combined with chemotherapy: Eloxatin 130mg/m2 2h ivgtt d1, Xeloda 1000mg/m2 bid po d1-14 Q21d ;Chemotherapy: Eloxatin 130mg/m2 2h ivgtt d1, Xeloda 1000mg/m2 bid po d1-14 Q21d | Guang'anmen Hospital affiliatied to China Academy of Chinese Medical Sciences; CHANGBAISHAN PHARMACEUTICAL CO., LTD, CHANGBAISHAN PHARMACEUTICAL CO., LTD | colorectal cancer | | | | |
2015-000689-79: Rectal preserving treatment for early rectal cancer. A multi-centred randomised trial of additional surgery versus additional chemoradiotherapy after local excision for early rectal cancers. |
|
|
| Ongoing | 4 | 302 | Europe | Xeloda, SAP-10073476, Tablet, Xeloda | Vrije Universiteit Medical Center, Vrije Universiteit Medical Center | Patients with a margin free (at least 1 mm) endoluminal local excision (by TEM, TAMIS, TSPM, EMR/ESD or polypectomy) of an early rectal cancer (below 10 cm). According to current guidelines these patients require additional surgery after the local excision due to tumor characteristics, Patients with an early rectal cancer that was removed by transanal excision that require addiotional surgery due to high risk tumor characteristics found in the pathology report., Diseases [C] - Cancer [C04] | | | | |
2005-000405-56: RANDOMIZED CLINICAL TRIAL TO COMPARE THE BENEFIT OF ADDING HERCEPTIN TO CAPECITABINE PLUS VINORELBINE AS SECOND LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED NON OPERABLE OR METASTATIC BREAST CANCER WITH OVEREXPRESSION OF HER-2, WHO HAVE PROGRESSED TO A PREVIOUS LINE OF TREATMENT FOR METASTATIC DISEASE WITH TRASTUZUMAB IN COMBINATION WITH TAXANES |
|
|
| Ongoing | 4 | 82 | Europe | NAVELBINE, NAVELBINE, XELODA, HERCEPTIN, NAVELBINE, XELODA, HERCEPTIN | GRUPO ESPAÑOL DE INVETIGACION EN CANCER DE MAMA (GEICAM) | PATIENTS WITH ADVANCED OR METASTATIC BREAST CANCER AND OVEREXPRESSION OF HER2. | | | | |
2008-004097-41: « OCTO : Quantification de l’impact des variations d’Observance d’une ChimioThérapie Orale par l’utilisation de piluliers électroniques et modélisation des marqueurs de toxicités» |
|
|
| Ongoing | 4 | 30 | Europe | XELODA, XELODA, XELODA | Hospices Civils de Lyon | Breast cancer femaleColorectal cancer | | | | |
2009-013029-41: Proteomic profile analysis to classify advanced pancreatic adenocarcinoma patients for clinical outcome after treatment with PDXG (cisplatin, docetaxel, capecitabine, gemcitabine) or PEXG (cisplatin, epirubicin, capecitabine, gemcitabine) regimen. |
|
|
| Ongoing | 4 | 100 | Europe | CISPLATINO TEVA, GEMZAR, FARMORUBICINA, XELODA, TAXOTERE, CISPLATINO TEVA, GEMZAR, FARMORUBICINA, XELODA, TAXOTERE | FONDAZIONE CENTRO S. RAFFAELE DEL MONTE TABOR | patients affected by adenocarcinoma at stage III or IV who are candidate to receive upfront chemotherapy according to PDXG or PEXG regimen. | | | | |
2010-022737-28: A randomised phase II screening trial with functional imaging and patient reported toxicity sub-studies comparing LApatiNib plus capecitabine versus continued Trastuzumab plus capecitabine after local therapy in patients with ERb B2 positive metastatic breast cancer developing braiN metastasis /es |
|
|
| Ongoing | 4 | 130 | Europe | TYKERB (Lapatinib), Herceptin (Trastuzumab), Xeloda (Capecitabine), GEW00474, RO 45-2317, TYKERB, Herceptin, Xeloda, TYKERB, Herceptin, Xeloda | Leeds Teaching Hospitals NHS Trust | Patients with ERB B2 positive metastatic breast cancer developing brain metastasis/es | | | | |
ChiCTR1800015434: Epidemiological study of cardiac toxicity derived from fluorouracil |
|
|
| Completed | 4 | 527 | | 5-Fu-based chemotherapy ;capecitabine-based chemotherapy | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, None | Solid tumors (colorectal, gastric, breast, esophageal and head and neck cancers) | | | | |
RESOLVE study, ChiCTR-IPR-15006283: A Randomized, multicenter, controlled study to compare perioperative chemotherapy of Oxaliplatin combined with S-1(SOX) versus SOX or oxaliplatin with capecitabine(XELOX) as post-operative chemotherapy in locally advanced gastric adenocarcinoma with D2 dissection |
|
|
| Recruiting | 4 | 1059 | | Capecitabine: 1000 mg/m2, take two times a day, 1-14 days ;S-1: 40~60mg bid, 1-14 days ;S-1 single oral dose, S-1: 40-60mg bid, 1-14 days | Beijing Cancer Hospital; Beijing Cancer Hospital, Beijing Cancer Hospital | Gastric adenocarcinoma | | | | |
2016-003325-41: PREemptive Pharmacogenomic testing for Preventing Adverse drug REactions (PREPARE) |
|
|
| Ongoing | 4 | 450 | Europe | Syrup, Tablet, Capsule, hard, Powder for injection, Capsule, Solution for injection, Concentrate for solution for infusion, Powder for solution for infusion, Codeine, Acenocoumarol, Amitriptyline, Aripiprazole, Atomoxetine, Atorvastatine, Azathioprine, Capecitabine, Carbamazepine, Citalopram, Clomipramine, Clopidogrel, Clozapine, Efavirenz, Escitalopram, Flecainide, Flucloxacillin, Fluorouracil, Haloperidol, Irinotecan, Mercaptopurine, Metoprolol, Oxycodone, Paroxetine, Phenprocoumon, Phenytoin, ORAP 1 mg Tabletten, Propafenone, Sertraline, Simvastatin, Tacrolimus, Tamoxifen, Tegafur, Tioguanine, Tramadol, Venlafaxine, Voriconazole, Zuclopenthixol, Ethinylestradiol, ORAP 4 mg Tabletten | Leiden University Medical Center, Leiden University Medical Center | Adverse drug reactions, Side-effects, Not possible to specify | | | | |
ChiCTR-IPR-15007047: Comparing the adjuvant chemotherapy regimens for advanced gastric cancer after laparoscopic D2 radical gastrectomy |
|
|
| Not yet recruiting | 4 | 100 | | Oxaliplatin 130mg/m2, iv drip d1; Capecitabine 1000mg/m2, Po, bid, d1-14, 21d/cycle, total of 8 cycles ;Oxaliplatin 130mg/m2, iv drip d1; S1 60mg, Po, bid, d1-14, 21d/cycle, total of 8 cycles. | Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Nil | gastric cancer | | | | |
2017-004465-27: The effects of the proton pump inhibitor esomeprazole alone or in combination with Coca-Cola on the absorption of Capecitabine in patients with cancer 'the COCA study' Het effect van de maagzuurremmer esomeprazol op de opname van capecitabine in het bloed bij patiënten met kanker |
|
|
| Ongoing | 4 | 28 | Europe | Film-coated tablet, Gastro-resistant tablet, capecitabine, Nexium | Erasmus MC Cancer Institute, Erasmus MC | Colorectal carcinoma or other solid tumours Colorectal carcinoom of een ander type solide tumor, Colorectal carcinoma or other solid tumours Darmkanker of een ander vorm van solide tumor, Diseases [C] - Cancer [C04] | | | | |
ChiCTR-OPC-17012186: An prospective, single-arm, multi-center clinical trial of Apatinib combined with capecitabine in the treatment of advanced ovarian cancer |
|
|
| Recruiting | 4 | 30 | | combined Capecitabine | The Second People's Hospital of Hefei; The Second People's Hospital of Hefei, self-financing | Ovarian cancer | | | | |
ChiCTR1800017323: A phase II study of apatinib combined with with XELOX regimen in the treatment of locally advanced gastric cancer |
|
|
| Recruiting | 4 | 20 | | apatinib combined with with XELOX regimen | The First Affliliated Hospital With Nangjing Medical University(Jiangsu Province Hospital); The First Affliliated Hospital With Nangjing Medical University(Jiangsu Province Hospital), Self financing | gastric cancer | | | | |
ChiCTR-IPR-16008926: Clinical study on the anti-cancer effect of fulvestrant combine with capecitabine in the postmenopausal breast cancer patients with estrogen receptor positive when progressive or recurrence after endocrine therapy. |
|
|
| Not yet recruiting | 4 | 200 | | fulvestrant ;fulvestrant combine with capecitabine | Department of Endocrine and Breast Surgery of the First Affiliated Hospital of Chongqing Medical University; Department of Endocrine and Breast Surgery of the First Affiliated Hospital of Chongqing Medical University, Pharmaceutical companies funding | breast cancer | | | | |
ChiCTR1800014504: Non-intervention study of apatinib combined with capecitabine versus capecitabine in the treatment of advanced metastatic colorectal cancer |
|
|
| Not yet recruiting | 4 | 138 | | Apatinib + capecitabine ;capecitabine | Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College, Self financing | Metastatic colorectal cancer | | | | |
ChiCTR1800018546: A clinical study for Neoadjuvant Chemotherapy using apatinib plus L-OHP and capecitabine in local advanced gastric cancer |
|
|
| Not yet recruiting | 4 | 48 | | Apatinib combined with XELOX | The First Hospital of Lanzhou University; The First Hospital of Lanzhou University Intervention Department, Self raise independently | Locally advanced gastric cancer | | | | |
ChiCTR-IPR-16009755: The prolonged adjuvant therapy with capecitabine after R0 surgery and perioperative chemotherapy for advanced colorectal cancer with only liver metastasis: a prospective, multicenter, randomized, controlled clinical study. |
|
|
| Recruiting | 4 | 188 | | observation ;Capecitabine | West China Hospital, Sichuan University; West China Hospital, Sichuan University, No fouding | colorectal cancer | | | | |
2017-002037-31: Study of the impact of DPD activity on the efficacy of capecitabine Etude de l’impact de l’activité DPD sur l’efficacité de la capécitabine |
|
|
| Not yet recruiting | 4 | 155 | Europe | Tablet, Xeloda | Centre Antoine-LACASSAGNE, Centre Antoine-LACASSAGNE, DGOS | Metastatic HER2-negative breast cancer, Metastatic breast cancer with negative HER2-Receptors, Diseases [C] - Cancer [C04] | | | | |
2019-004003-12: A study of the dosage of the medicine 5-FU or capecitabine based on genetic testing and lab test results Een studie omtrent de dosering van het geneesmiddel fluorouracil of capecitabine op basis van genetische gegevens en bloeduitslagen |
|
|
| Not yet recruiting | 4 | 300 | Europe | Concentrate for solution for injection/infusion, Tablet, Fluorouracil accord healthcare (5g/100 ml), Xeloda 150 mg, Xeloda 500 mg | Jessa Hospital, Jessa Hospital | Gastro-intestinal cancers: stomach, pancreas, colon, rectum, anal tumors, esophagus Gastro-intestinale kankers: maag, pancreas, dikke darm, rectum, anale tumoren, slokdarm, Cancer: stomach, pancreas, colon, rectum, anal tumors, esophagus Kanker: maag, pancreas, dikke darm, rectum, anale tumoren, slokdarm, Diseases [C] - Cancer [C04] | | | | |
ChiCTR1800014477: Mesylate apatinib as monotherapy or in combination with capecitabine in the treatment of advanced breast cancer multicenter, open, single arm clinical study |
|
|
| Not yet recruiting | 4 | 96 | | apatinib or apatinib plus capecitabine | Sui'ning Central Hospital; Sui'ning Central Hospital, Self financing | advanced breast cancer | | | | |
| Completed | 4 | 100 | | Pharmacological interventions | First Affiliated Hospital of Zhejiang University; First Affiliated Hospital of Zhejiang University, Self-collected funds | Advanced breast cancer | | | | |
ChiCTR1800018673: One-arm, single-center, open-label clinical study for apatinib combined with capecitabine in the treatment of advanced triple-negative breast cancer |
|
|
| Recruiting | 4 | 30 | | apatinib combined with capecitabine | The First Affiliated Hospital of Chongqing Medical University; The First Affiliated Hospital of Chongqing Medical University, Jiangsu hengrui pharmaceutical co. LTD | advanced triple-negative breast cancer | | | | |
2020-001938-35: AIRE: Investigation of the immune response after chemotherapy treatment with Eribulin: A trial for female patients with advanced breast cancer. AIRE: Untersuchung der Immunantwort nach Behandlung mit der Chemotherapie Eribulin: Eine Studie für Patientinnen mit fortgeschrittenem Brustkrebs. |
|
|
| Not yet recruiting | 4 | 84 | Europe | Eribulin, Paclitaxel, Paclitaxel Albumin-Bound, Capecitabine, Vinorelbine, Solution for injection, Concentrate for solution for infusion, Powder for solution for infusion, Tablet, Halaven, Paclitaxel, nab-Paclitaxel, Capecitabine, Vinorelbine | Institut für Frauengesundheit GmbH, Institut für Frauengesundheit (IFG) GmbH | Female patients diagnosed with HER2 negative advanced breast cancer, which had received at least one previous chemotherapy Patientinnen, die mit einem HER2 negativen Brustkrebs im fortgeschrittenem Stadium diagnostiziert wurden und zuvor mindestens eine Chemotherapie erhielten., Female patients which were diagnosed with advanced breast cancer. The tumor should not have a certain marker (HER2) on its surface (HER2 negative breast cancer). Patientinnen, die mit einem Brustkrebs im fortgeschrittenem Stadium diagnostiziert wurden. Den Tumorzellen fehlt ein bestimmter Marker (HER2) auf der Oberfläche (HER2-negativer Brustkrebs)., Diseases [C] - Cancer [C04] | | | | |
ChiCTR1800018415: Clinical study for exemestane with metronomic capecitabine in the second-line treatment of metastatic breast cancer |
|
|
| Not yet recruiting | 4 | 60 | | exemestane ;exemestane with metronomic capecitabine | Department of Oncology, East District of Suzhou Municipal Hospital; Suzhou Municipal Hospital, Beijing medical and health foundation | breast cancer | | | | |
ChiCTR1900024095: Exploratory clinical study for PD1 monoclonal antibody SHR1210 combined with apatinib or capecitabine versus capecitabine in the treatment of advanced pancreatic cancer |
|
|
| Recruiting | 4 | 36 | | PD-1 monoclonal antibody combined with Apatinib versus PD-1 monoclonal antibody combined with capecitabine versus capecitabine alone | Shanghai General Hospital; Shanghai General Hospital, Self financing | pancreatic cancer | | | | |
ChiCTR1800015601: A prospective randomized controlled trial of Apatinib or S-1 or Capecitabine as Maintence Trerapy after radical correction of tumors of the biliary tract |
|
|
| Recruiting | 4 | 160 | | Apatinib ;S-1 ;Capecitabine ;placebo | JIANGSU HENGRUI MEDICINE CO., LTD.; West China Hospital of Sichuan University, 1. Hengrui Company, Jiangsu, China; 2. self-raised funds | tumors of the biliary tract | | | | |
ChiCTR2000040027: Prophylactic administration of recombinant human thrombopoietin in the secondary prevention of thrombocytopenia induced by XELOX adjuvant chemotherapy in patients with stage III colorectal cancer |
|
|
| Recruiting | 4 | 30 | | Preventive use of recombinant human thrombopoietin | Ordos Central Hospital, Inner Mongolia; Ordos Central Hospital, Innovation and Entrepreneurship Project of Ordos Health Commission、Independent scientific research project of Ordos Central Hospital | Malignant tumor | | | | |
ChiCTR1900023851: To study the therapeutic effect of oral vinorelbine soft capsule combined with capecitabine on HER2 negative advanced breast cancer. |
|
|
| Recruiting | 4 | 100 | | vinorelbine soft capsule combined with capecitabine ;capecitabine | Hubei Cancer Hospital; Hubei Cancer Hospital, self-raised | breast cancer | | | | |
ChiCTR1800020419: A single-center prospective randomized controlled trial for tiggio combined with oxaliplatin (SOX) versus capecitabine combined with oxaliplatin (XELOX) in the treatment of postoperative adjuvant chemotherapy in patients with colorectal cancer |
|
|
| Not yet recruiting | 4 | 60 | | SOX ;XELOX | Yixing People's hospital; Yixing People's hospital, self-funded | colorectal cancer | | | | |
ChiCTR2000028933: Safety and Efficacy Evaluation Study of Brucea javanica oil in the Treatment of Advanced Gastric Cancer |
|
|
| Recruiting | 4 | 60 | | Brucea Javanica Oil ;Capecitabine or Tegio | Jiangsu Cancer Hospital; Jiangsu Cancer Hospital, Project | Gastric Cancer | | | | |
| Recruiting | 4 | 175 | Europe | PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy | IRCCS San Raffaele | Pancreatic Ductal Adenocarcinoma | 01/22 | 01/26 | | |
NCT04767828: A Single Arm Study of Brain Metastasis in Patients With HER2-positive Breast Cancer |
|
|
| Recruiting | 4 | 43 | RoW | PYRROTINI, CAPECITABINE, Brain radiation therapy | Tianjin Medical University Cancer Institute and Hospital | TTP | 06/22 | 06/22 | | |
ChiCTR2000031388: Clinical study on the treatment of second-line and above HER2 negative advanced breast cancer with anrotinib combined with capecitabine |
|
|
| Not yet recruiting | 4 | 44 | | Capecitabine ;Anrotinib combined with Capecitabine | Chongqing University Three Gorges Hospital; Chongqing University Three Gorges Hospital, Subject of chongqing health and fitness commission | Breast Cancer | | | | |
ChiCTR2000041418: A prospective, randomized controlled, open-label study of adjuvant capecitabine after CK19-related liver cancer surgery |
|
|
| Recruiting | 4 | 130 | | Oral capecitabine ;TACE ;Oral capecitabine ;TACE | Department of Hepatobiliary Surgery, Cancer Hospital Affiliated to Guangxi Medical University; Cancer Hospital Affiliated to Guangxi Medical University, self-raised | Hepatocellular Carcinoma | | | | |
ChiCTR2000029145: A multicenter, phase III, randomized, double-blind, controlled trial for the efficacy and safety of capecitabine induced hand foot syndrome by Prophylactic using of mecobalamin in breast cancer patients |
|
|
| Recruiting | 4 | 288 | | Mecobalamin ;placebo | Sun Yat-Sen Memorial Hospital; Sun Yat-Sen Memorial Hospital, raise independently | breast cancer | | | | |
ChiCTR1900025004: Nab-paclitaxel plus capecitabine as first-line treatment of recurrent/metastatic cholangi ocarcinoma: a multi-center, open label, single-arm study |
|
|
| Recruiting | 4 | 46 | | Nab-Paclitaxel 150 mg/m2, iv, d1； capecitabine 2g/m2, po, d1-7; Q2W，until disease progression or unacceptable toxicity | Beijing Cancer Hospital; Beijing Cancer Hospital and Institute, SHIYAO Group OUYI Pharmaceutical Co. Ltd. | recurrent/metastatic cholangiocarcinoma | | | | |
ChiCTR2000036879: A single-arm, open, exploratory clinical study of portal vein embolization followed by Camrelizumab combined with capecitabine neoadjuvant therapy before radical resection of hilar cholangiocarcinoma |
|
|
| Not yet recruiting | 4 | 30 | | Camrelizumab: medication once every 3 weeks; capecitabine tablets: taking 14 consecutive days, stopping the drug for 7 days, 21 days as a treatment cycle | Eastern Hepatobiliary Surgery Hospital; Eastern Hepatobiliary Surgery Hospital, Raise yourself | Cholangiocarcinoma | | | | |
ChiCTR2000041223: Efficacy and mechanism of pyrrolitinib combined with capecitabine with/without trastuzumab for metastatic breast cancer failed with anti-HER2 therapy |
|
|
| Recruiting | 4 | 130 | | Capecitabine plus pyrrolotinib plus trastuzumab ;Capecitabine plus pyrrolotinib | Jiangxi Cancer Hospital; Jiangxi Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd ；Shanghai Fuhong Hanlin Biotechnology Co., Ltd | Breast Cancer | | | | |
PADMA, NCT03355157 / 2016-004482-89: A Randomized, Open-label, Multi-center Phase IV Study Evaluating Palbociclib Plus Endocrine Treatment Versus a Chemotherapy-based Treatment Strategy in Patients With Hormone Receptor Positive / HER2 Negative Breast Cancer in a Real World Setting (GBG 93 - Study). |
|
|
| Recruiting | 4 | 150 | Europe | Palbociclib / Chemotherapy (capecitabine, epirubicin, paclitaxel, vinorelbine) / Endocrine therapy (exemestane, fulvestrant, letrozole, tamoxifen) | German Breast Group, Pfizer, AMS Advanced Medical Services GmbH | Metastatic Breast Cancer | 03/23 | 03/23 | | |
ChiCTR-IPR-17013680: Comparison of adjuvant chemotherapy after laparoscopic D2 radical surgery for advanced gastric cancer |
|
|
| Not yet recruiting | 4 | 180 | | Oxaliplatin 130mg / m2, intravenous infusion of the first day; capecitabine 1000mg / m2, orally, 2 times / day, 1-14 days, 21 days for a cycle. A total of 8 cycles. ;Oxaliplatin 130mg / m2, intravenous infusion of the first day; Tegafur 60mg/time, oral, two time a day in day 1 to day 14, 21 days a cycle, total 8 cycles. | Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Tianjin Medical University clinical research project | gastric cancer | | | | |
ChiCTR2100046202: Efficacy and safety of Sintilimab and oxaliplatin in combination with capecitabine or in combination with paclitaxel/albumin paclitaxel in first-line treatment of unresectable locally advanced, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma |
|
|
| Recruiting | 4 | 100 | | Immunotherapy combined with chemotherapy | Nanping First Hospital Affiliated to Fujian Medical University; Nanping First Hospital Affiliated to Fujian Medical University, Cinda Biopharmaceutical (Suzhou) Co., Ltd | gastric and gastroesophageal junction adenocarcinoma | | | | |
ChiCTR2200060671: GEMOX 'chemo holiday' combined with regorafenib and toripalimab for biliary tract cancers with high-risk recurrence after surgery: a multicenter prospective cohort study |
|
|
| Not yet recruiting | 4 | 120 | China | ① GEMOX: a total of 6 courses of treatment. 1 course of treatment was suspended after every 2 courses of treatment. ② Regorafenib: a total of 8 courses of treatment. ③ Toripalimab: a total of 8 courses of treatment. ④ Capecitabine: a total of 8 courses of treatment. ;① GEMOX: a total of 6 courses of treatment. ② Regorafenib: a total of 8 courses of treatment. ③ Toripalimab: a total of 8 courses of treatment. ④ Capecitabine: a total of 8 courses of treatment. ;① GEMOX: a total of 6 courses of treatment. ② Capecitabine: a total of 8 courses of treatment. | Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine ; Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, This work was supported by Scientific Research Fund of Zhejiang Provincial Education Department (Y202148325), and National Natural Science Foundation of China (81800540, 81827804, and 81802330). | Biliary tract cancers | | | | |
ChiCTR2200060670: GEMOX combined with regorafenib in 'chemo holiday' for biliary tract cancers with high-risk recurrence after surgery: a multicenter prospective cohort study |
|
|
| Not yet recruiting | 4 | 120 | | ① GEMOX: 6 courses. 1 course was suspended after every 2 courses of treatment. ② Regorafenib: 8 courses of treatment. ③ Capecitabine: 8 courses of treatment. ;① GEMOX: 6 courses of treatment. ② Regorafenib: 8 courses of treatment. ③ Capecitabine: 8 courses of treatment. ;① GEMOX: 6 courses of treatment. ② Capecitabine: 8 courses of treatment. | Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine; Sir Run-Run Shaw Hospital, Zhejiang University School of Medicine, This work was supported by Scientific Research Fund of Zhejiang Provincial Education Department (Y202148325), and National Natural Science Foundation of China (81800540, 81827804, and 81802330). | Biliary tract cancers | | | | |
NCT04747951: Total Neoadjuvant Therapy in Rectal Cancer Treatment |
|
|
| Recruiting | 4 | 280 | RoW | Concurrent Chemoradiotherapy, Radiotherapy, TME, consolidation chemotherapy, XELOX, CAPOX, adjuvant chemotherapy, mFOLFOX | State Scientific Centre of Coloproctology, Russian Federation | Rectal Cancer | 10/23 | 11/23 | | |
ChiCTR2100042385: A prospective, non-randomized, multi-cohort study of apatinib mesylate combined with XeLox-based protocol for perioperative treatment of resectable gastric cancer |
|
|
| Recruiting | 4 | 101 | | Apatinib mesylate + carririzumab + capetabine + oxaliplatin ;Apatinib mesylate + capetabine + oxaliplatin | Tangdu Hospital of Air Force Medical University; Tangdu Hospital of Air Force Military Medical University, self-raised | Cancer of the stomach | | | | |
OBU-BC-II-101, NCT06217185: The Efficacy and Safety of Pyrotinib, Trastuzumab Combined With Taxanes in the Treatment of Trastuzumab-treated HER2+ Advanced Breast Cancer (ABC). |
|
|
| Recruiting | 4 | 100 | RoW | Pyrotinib, Trastuzumab, Taxanes, Capecitabine | Hebei Medical University Fourth Hospital | HER2-positive Breast Cancer, Advanced Breast Cancer | 12/25 | 06/27 | | |
NCT06230055: Intrathecal Chemotherapy Through Ommaya Reservoir Upon Her-2 Negative Breast Cancer With Leptomeningeal Metastasis |
|
|
| Recruiting | 4 | 48 | RoW | Ommaya reservoir, Systematic chemotherapy | Fudan University | HER2-negative Breast Cancer, Leptomeningeal Metastasis | 01/26 | 01/27 | | |
NCT06387368: Clinical Study of Huaier Granule in the Treatment of Unresectable Pancreatic Cancer |
|
|
| Not yet recruiting | 4 | 488 | NA | Huaier Granule, Z20000109#NMPA Approval Number#, Capecitabine, Standard chemotherapy | Health Science Center of Xi'an Jiaotong University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Pancreatic Cancer Non-resectable | 03/28 | 08/28 | | |
NCT06368063: The Study of Huaier Granule in Postoperative Adjuvant Therapy of Resectable Pancreatic Cancer |
|
|
| Recruiting | 4 | 642 | RoW | Huaier granule, Z20000109#NMPA Approval Number#, chemotherapy drugs, Standard chemotherapy | Health Science Center of Xi'an Jiaotong University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Pancreatic Cancer Resectable | 03/26 | 03/28 | | |
ChiCTR2000030887: The efficacy and safety of triple-drug regimen of docetaxel, oxaliplatin combing with capecitabine and two-drug regimen of oxaliplatin combing with capecitabine in the treatment of adenocarcinoma at the junction of stomach and gastroesophageal in IIIB and IIIc stage: a randomized controlled phase III clinical study |
|
|
| Not yet recruiting | 4 | 196 | | docetaxel plus oxaliplatin and capecitabine ;oxaliplatin plus capecitabine | He'nan Cancer Hospital; Henan Cancer Hospital, self-raised | Gastric carcinoma | | | | |
ChiCTR2000032696: Clinical study of carrelizumab combined with chemotherapy in perioperative treatment of patients with locally advanced gastric adenocarcinoma |
|
|
| Not yet recruiting | 4 | 30 | | preoperative：Carrelizumab combined with DOX;postoperation:Carrelizumab combined with capecitabine | Tianjin Cancer Hospital; Tianjin Cancer Hospital, Self-funding | Gastric adenocarcinoma | | | | |
ChiCTR2100047149: Capecitabine metronomic chemotherapy for maintenance treatment of metastatic colorectal cancer after reaching NED (no evidence of disease): a prospective, single center, randomized, controlled clinical study |
|
|
| Recruiting | 4 | 60 | | Capecitabine 500mg po bid ;watch and wait | Zhongshan Affiliated Hospital, Guangzhou University of Chinese Medicine; Zhongshan Affiliated Hospital，Guangzhou University of Chinese Medicine, Self-raised funds and funded by zhongshan medical and health research program | Colorectal cancer | | | | |
CRC - PTX, NCT06115174: Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer |
|
|
| Not yet recruiting | 4 | 44 | NA | Pentoxifylline, FOLFOX, XELOX, Monoclonal antibodies (target therapy) | Tanta University | Metastatic Colorectal Carcinoma | 11/24 | 12/24 | | |
ChiCTR2100052828: Multicenter, randomized study of eribulin plus capecitabine versus capecitabine in HER2-negative patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes |
|
|
| Recruiting | 4 | 320 | | Eribulin mesilate 1.4 mg/m^2 intravenously over 2-5 minutes on days 1 and 8 of every 21-day cycle, in combine with Capecitabine tablet 1000 mg/m^2 orally bid for days 1 to 14 of every 21-day cycle ;Capecitabine tablet 1250 mg/m^2 orally bid for days 1 to 14 of every 21-day cycle | Cancer Hospital Chinese Academy of Medical Sciences; Cancer Hospital Chinese Academy of Medical Sciences, Eisai China lnc. | Breast cancer | | | | |
ChiCTR2300074767: Open-label, single-arm, single-center Phase Ib/ II clinical study of fruquintinib combined with trastuzumab and XELOX in the first-line treatment of advanced HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma |
|
|
| Recruiting | 4 | 51 | | fruquintinib combined with trastuzumab and XELOX | Henan Cancer Hospital; Henan Cancer Hospital, CSCO Fund | Adenocarcinoma of the stomach or gastroesophageal junction | | | | |
ChiCTR1800019987: Maintenance treatment of capecitabine in patient with HER 2-positive and triple negative breast cancer: a randomized, open label, blank controlled, multicenter trial |
|
|
| Recruiting | 4 | 1190 | | Capecitabine ;None | Suining Central Hospital; Suining Central Hospital, Beijing Medical and Health Foundation | breast cancer | | | | |
ChiCTR2300068266: Tirelizumab plus Lunvatinib and capecitabine for first-line treatment of advanced intrahepatic cholangiocarcinoma unsuitable for GP chemotherapy |
|
|
| Not yet recruiting | 4 | 36 | China | 1. Tirelizumab: 200mg, q3w, intravenous drip, lasting for 1 year, or until the disease progresses or intolerable adverse reactions occur; 2. Remvastinib: 8mg, qd, oral, until the disease progresses or intolerable adverse reactions occur; 3. Capecitabine: 1000mg/m2, bid, oral, take it for 2 weeks, stop for 1 week | The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital) ; The Third Affiliated Hospital of Naval Medical University (Eastern Hepatobiliary Surgery Hospital), BeiGene (Beijing), Ltd. | advanced intrahepatic cholangiocarcinoma | | | | |
ChiCTR2300073771: A single-arm, prospective, multicenter, real-world study of efficacy and safety of fuquinitinib combined with capecitabine in maintenance therapy after first-line chemotherapy in metastatic colorectal cancer |
|
|
| Not yet recruiting | 4 | 152 | | The dose of fuquinitinib was 5mg, qd po, d1-14, q3w;The dose of capecitabine was 1000mg/m2, bid po, d1-14, q3w. | Shanghai East Hospital ；Shanghai Tenth People’s Hospital; Shanghai East Hospital, Shanghai East Hospital | colorectal cancer | | | | |
NCT05148767: UGT1A1-Based Irinotecan Therapy for Locally Advanced Rectal Cancer |
|
|
| Recruiting | 4 | 606 | RoW | Neoadjuvant chemoradiotherapy based on irinotecan | Zhejiang Cancer Hospital | Rectal Cancer Stage III | 06/26 | 12/26 | | |
ChiCTR2300069145: Utidelone plus capecitabine for inoperable local advanced HER2 negative breast cancer with no response to neoadjuvant anthracycline and taxane treatment: a multi-center, single-arm exploratory study |
|
|
| Recruiting | 4 | 30 | | utiderone plus capecitabine | Guangdong Provincial Hospital of Traditional Chinese Medicine; Guangdong Provincial Hospital of Traditional Chinese Medicine, Chengdu Huahao Zhongtian Biological Co., Ltd. | breast cancer | | | | |
ChiCTR2100046285: A multicenter, open, parallel randomized controlled clinical study of amlotinib in neoadjuvant and adjuvant use in patients undergoing surgery for esophageal and esophagogastric junction (EC/GEJC) malignancies |
|
|
| Recruiting | 4 | 90 | | Anlotinib + nedaplatin + capecitabine ;Nedaplatin + capecitabine | The Second Hospital of Shandong University; The Second Hospital of Shandong University, Beijing Kangmeng Charity Foundation | Malignant tumors of the esophagus/esophagogastric junction | | | | |
NCT05498766: Effect and Safety of Huaier Granule Versus SOX Regimen in Gastric Cancer Patients |
|
|
| Not yet recruiting | 4 | 702 | RoW | Huaier granule, Z20000109, Oxaliplatin, Tegafur, Gimeracil and Oteracil Potassium | Wuhan Union Hospital, China, LinkDoc Technology (Beijing) Co. Ltd. | Gastric Cancer | 07/29 | 11/29 | | |
ChiCTR2300069272: An exploratory study of stereotactic body radiotherapy sequencing camrelizumab and capecitabine for patients with locally advanced pancreatic cancer |
|
|
| Recruiting | 4 | 37 | | stereotactic body radiotherapy sequencing camrelizumab and capecitabine | Sir Run Run Shaw Hospital (SRRSH) Affiliated to the Zhejiang University School of Medicine; Sir Run Run Shaw Hospital (SRRSH) Affiliated to the Zhejiang University School of Medicine, self-raised | pancreatic cancer | | | | |
